BIRC6-AS2

Across TCGA pan-cancer cohorts, BIRC6-AS2 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of BIRC6-AS2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where BIRC6-AS2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BIRC6-AS2 is over-expressed in tumor.

BLCA, CHOL, and STAD are the cancer types where BIRC6-AS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BIRC6-AS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	All	+0.387	.005	5	view →
CHOL	All	All	+0.456	.002	3	view →
STAD	All	II,III,IV	+0.314	.022	3	view →
LUAD	Male	III,IV	+0.191	.009	2	view →
LUSC	All	All	+0.164	.005	2	view →
COAD	Female	All	+0.127	.046	1	view →
HNSC	All	All	+0.067	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

BIRC6-AS2–BLCA

Open the BLCA breakdown →